For an initial clinical proof of concept validation, we aggregated 3,003 breast cancer biopsy samples across 19 cohorts and identified a significant association between our TP53-loss phenocopy signature and pathologic complete response and extent of residual disease after neoadjuvant chemotherapy in early-stage breast cancer. This evidence concerns the gene TP53 and breast cancer.